REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 154 filers reported holding REATA PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $287,683,913 | +15.0% | 2,821,537 | +2.6% | 0.01% | +16.7% |
| Q1 2023 | $250,115,555 | +143.3% | 2,750,941 | +1.7% | 0.01% | +100.0% |
| Q4 2022 | $102,787,872 | +54.2% | 2,705,656 | +2.0% | 0.00% | +50.0% |
| Q3 2022 | $66,677,000 | -16.2% | 2,653,300 | +1.3% | 0.00% | 0.0% |
| Q2 2022 | $79,604,000 | -8.1% | 2,619,410 | -0.9% | 0.00% | 0.0% |
| Q1 2022 | $86,587,000 | +28.4% | 2,643,082 | +3.3% | 0.00% | 0.0% |
| Q4 2021 | $67,446,000 | -73.6% | 2,557,673 | +0.7% | 0.00% | -66.7% |
| Q3 2021 | $255,599,000 | -28.9% | 2,540,490 | +0.1% | 0.01% | -33.3% |
| Q2 2021 | $359,282,000 | +48.0% | 2,538,560 | +4.3% | 0.01% | +28.6% |
| Q1 2021 | $242,719,000 | -15.4% | 2,434,499 | +4.9% | 0.01% | -12.5% |
| Q4 2020 | $286,801,000 | +39.3% | 2,320,031 | +9.7% | 0.01% | +14.3% |
| Q3 2020 | $205,956,000 | -40.1% | 2,114,097 | -4.1% | 0.01% | -41.7% |
| Q2 2020 | $343,798,000 | +6.3% | 2,203,551 | -1.6% | 0.01% | -14.3% |
| Q1 2020 | $323,282,000 | -27.0% | 2,239,728 | +3.4% | 0.01% | -6.7% |
| Q4 2019 | $442,976,000 | +201.3% | 2,166,886 | +18.3% | 0.02% | +200.0% |
| Q3 2019 | $147,045,000 | -10.9% | 1,831,425 | +4.7% | 0.01% | -16.7% |
| Q2 2019 | $165,062,000 | +14.6% | 1,749,451 | +3.8% | 0.01% | 0.0% |
| Q1 2019 | $144,003,000 | +104.0% | 1,684,842 | +33.9% | 0.01% | +100.0% |
| Q4 2018 | $70,587,000 | -27.3% | 1,258,234 | +5.9% | 0.00% | -25.0% |
| Q3 2018 | $97,101,000 | +309.4% | 1,187,632 | +75.1% | 0.00% | +300.0% |
| Q2 2018 | $23,719,000 | +85.1% | 678,306 | +8.6% | 0.00% | 0.0% |
| Q1 2018 | $12,813,000 | -26.1% | 624,674 | +2.0% | 0.00% | 0.0% |
| Q4 2017 | $17,349,000 | +8.0% | 612,642 | +18.6% | 0.00% | 0.0% |
| Q3 2017 | $16,061,000 | +71.8% | 516,446 | +74.7% | 0.00% | – |
| Q2 2017 | $9,350,000 | +192.7% | 295,540 | +109.6% | 0.00% | – |
| Q1 2017 | $3,194,000 | +2.4% | 141,025 | -1.3% | 0.00% | – |
| Q4 2016 | $3,119,000 | -7.1% | 142,880 | +12.2% | 0.00% | – |
| Q3 2016 | $3,358,000 | +255.0% | 127,398 | +165.9% | 0.00% | – |
| Q2 2016 | $946,000 | – | 47,915 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 2,896,901 | $291,457,000 | 32.14% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 46,646 | $4,693,000 | 5.31% |
| Ikarian Capital, LLC | 471,400 | $47,423,000 | 3.34% |
| Duquesne Family Office | 695,033 | $69,927,000 | 2.27% |
| Camber Capital Management LP | 685,000 | $68,918,000 | 2.12% |
| LBJ Family Wealth Advisors, Ltd. | 30,359 | $3,054,000 | 1.82% |
| MADDEN SECURITIES Corp | 33,127 | $3,333,000 | 1.80% |
| Biondo Investment Advisors, LLC | 104,120 | $10,475,000 | 1.80% |
| Tolleson Wealth Management, Inc. | 60,750 | $6,112,000 | 1.73% |
| Keel Point, LLC | 97,074 | $9,767,000 | 1.26% |